We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals

135 hedge funds and large institutions have $458M invested in Amphastar Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 39 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 39

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

4% more capital invested

Capital invested by funds: $442M → $458M (+$15.8M)

1% more funds holding

Funds holding: 134135 (+1)

0.3% less ownership

Funds ownership: 48.21%47.91% (-0.3%)

Holders
135
Holders Change
+1
Holders Change %
+0.75%
% of All Funds
2.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
58
Reduced
39
Closed
18
Calls
$221K
Puts
Net Calls
+$221K
Net Calls Change
+$221K
Name Holding Trade Value Shares
Change
Change in
Stake
Arrowstreet Capital
26
Arrowstreet Capital
Massachusetts
$3.08M +$3.37M +150,541 New
Allianz Asset Management
27
Allianz Asset Management
Germany
$2.56M +$4.66K +208 +0.2%
Deutsche Bank
28
Deutsche Bank
Germany
$2.44M +$969K +43,237 +57%
Skandinaviska Enskilda Banken (SEB)
29
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.39M -$11.2K -500 -0.4%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$2.17M +$48.8K +2,177 +2%
AllianceBernstein
31
AllianceBernstein
Tennessee
$2.08M -$473K -21,110 -17%
Bessemer Group
32
Bessemer Group
New Jersey
$2.04M +$659K +29,400 +42%
Legal & General Group
33
Legal & General Group
United Kingdom
$1.67M +$171K +7,623 +10%
QI
34
QS Investors
New York
$1.52M
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
$1.49M +$843K +37,628 +107%
Bank of America
36
Bank of America
North Carolina
$1.47M +$1.11M +49,346 +216%
TCIM
37
TIAA CREF Investment Management
New York
$1.47M -$5.51K -246 -0.3%
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$1.46M +$1.03M +45,966 +180%
AIM
39
Alambic Investment Management
California
$1.4M +$1.21M +53,800 +364%
MSL
40
Mackay Shields LLC
New York
$1.32M -$408K -18,200 -22%
SAM
41
Sawgrass Asset Management
Florida
$1.3M +$1.16M +51,890 +443%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.29M +$29.1K +1,300 +2%
SEI Investments
43
SEI Investments
Pennsylvania
$1.27M -$875K -39,046 -39%
Prudential Financial
44
Prudential Financial
New Jersey
$1.27M +$4.73K +211 +0.3%
KBC Group
45
KBC Group
Belgium
$1.14M
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$1.1M -$70.2K -3,135 -6%
ASRS
47
Arizona State Retirement System
Arizona
$1.09M +$2.04K +91 +0.2%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$1.05M +$67.3K +3,003 +6%
State Board of Administration of Florida Retirement System
49
State Board of Administration of Florida Retirement System
Florida
$998K +$559K +24,955 +104%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$977K +$244K +10,900 +30%

AMPH Hedge Fund Activity: Q1 2019 in Review

135 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2019, worth a combined $458M — up 3.6% from $442M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AMPH positions and 18 closed out — a net gain of 2 holders — while 58 added to existing stakes and 39 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.81M. The largest seller was Invesco, cutting an estimated $5.51M.

  • 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2019, up from 134 in Q4 2018.
  • Funds reported $458M of Amphastar Pharmaceuticals stock for Q1 2019, up 3.6% quarter-over-quarter.
  • 20 funds opened new Amphastar Pharmaceuticals positions in Q1 2019 and 18 closed out, a net change of +2 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q1 2019 was Morgan Stanley, an estimated $3.81M added.
  • The largest Amphastar Pharmaceuticals seller in Q1 2019 was Invesco, an estimated $5.51M sold.

Based on aggregated 13F filings for Q1 2019.